Discovery & Mechanism-Guided Design
Define the target pair, intended biology, binding geometry, valency, and architecture before construct generation begins.
Explore design servicesFrom target-pair strategy and molecular architecture to production, characterization, and preclinical research, we help scientific teams build evidence around the decisions that shape a bispecific antibody program.
Creative Biolabs provides integrated research and development services for bispecific and multispecific antibody programs. We work with academic, biotechnology, and pharmaceutical teams to address the scientific and technical challenges associated with target selection, molecular format, chain pairing, expression, purification, developability, functional validation, and early preclinical decision-making.
Our focus is not on delivering isolated assays or standard constructs. We build application-driven, mechanism-aware workflows that connect molecular design with manufacturability and biological function, helping teams move from an early concept to a well-characterized research candidate with clearer evidence for the next decision.
The performance of a bispecific antibody depends on how design variables work together. We evaluate these variables in the context of the complete molecule and its intended research use.
Each stage is planned around the same program question, so molecular design, material generation, analytical data, and biological evidence remain connected.
Define the target pair, intended biology, binding geometry, valency, and architecture before construct generation begins.
Explore design servicesDevelop IgG-like, fragment-based, fusion, conjugate, and multispecific formats with function and downstream studies in view.
Explore engineeringGenerate fit-for-purpose material through recombinant, cell-free, high-throughput, conjugation, or hybrid-hybridoma routes.
Explore purificationEvaluate identity, purity, structure, stability, binding, and mechanism-aligned functions, with in vitro and in vivo strategies selected for the program question.
Explore analysisIntegrate developability, sequencing, PK/PD, and preclinical studies to compare candidates and reveal risks beyond potency.
Explore platformsOur portfolio supports different mechanisms, molecular architectures, emerging modalities, and acceleration strategies rather than forcing every program into one scaffold or workflow.
T-cell, NK-cell, and macrophage engagers; signaling interference; forced protein association; pretargeting; and payload delivery.
IgG-like BsAbs, pairing strategies, tandem scFv, diabody, single-domain antibody, minibody, Fab fragments, fusion proteins, Fc fusions, and conjugates.
Biparatopic and trispecific antibodies, bispecific ADCs, bispecific aptamers, aptamer-drug conjugates, antibody mimetics, and BBB-penetrating concepts.
High-throughput parent-antibody screening and expression, AI-assisted optimization, cell-free expression, sequencing, and developability assessment.
Bispecific and multispecific formats can redirect immune cells, modulate more than one disease pathway, increase target selectivity, transport payloads, or enable new binding geometries. We tailor project design to the biology and research objective rather than to a single therapeutic area.
Our capabilities can support diverse research applications wherever coordinated target engagement may provide a useful experimental strategy.
Projects can begin with a target pair, a defined construct, existing material, or a specific technical bottleneck. The workflow is shaped around what the program needs to learn next.
Clarify the target pair, mechanism, study context, available materials, and the decision the project must support.
Recommend the format, engineering route, expression system, purification approach, and analytical package.
Produce constructs and evaluate them using fit-for-purpose biochemical, biophysical, binding, and functional methods.
Review results together to compare candidates, identify risks, and select the next design or study decision.
Our role is to make the scientific and technical trade-offs visible, so the next program decision is supported by a coherent body of evidence.
SERVICES
PRODUCTS
PLATFORMS